FOLLOWING a rebuffed bid by
pharmaceutical giant Sanofi to
acquire oncology biotech company
Medivation, AstraZeneca (AZ) is
now being linked to a $10 billion
bid, according to a report by
FierceBiotech.
Blockbuster prostate cancer drug
Xtandi (also sold by Astellas) is the
jewel attracting all the attention in
Medivation which is consequently
said to be valued at up to $8.7
billion, according to sources
speaking with the UK newspaper
Sunday Times.
While Sanofi may be going
“hostile” according to Reuters, AZ
may prove to be a white knight,
providing it can outbid other
rumoured oncology-oriented
suitors such as Roche, Amgen or
Gilead.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Apr 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.